Viral Vectors in Gene Therapy
- PMID:29883422
- PMCID: PMC6023384
- DOI: 10.3390/diseases6020042
Viral Vectors in Gene Therapy
Abstract
Applications of viral vectors have found an encouraging new beginning in gene therapy in recent years. Significant improvements in vector engineering, delivery, and safety have placed viral vector-based therapy at the forefront of modern medicine. Viral vectors have been employed for the treatment of various diseases such as metabolic, cardiovascular, muscular, hematologic, ophthalmologic, and infectious diseases and different types of cancer. Recent development in the area of immunotherapy has provided both preventive and therapeutic approaches. Furthermore, gene silencing generating a reversible effect has become an interesting alternative, and is well-suited for delivery by viral vectors. A number of preclinical studies have demonstrated therapeutic and prophylactic efficacy in animal models and furthermore in clinical trials. Several viral vector-based drugs have also been globally approved.
Keywords: approved drugs; clinical trials; gene silencing; immunotherapy; prevention; therapy.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
- Viral vectors engineered for gene therapy.Lundstrom K.Lundstrom K.Int Rev Cell Mol Biol. 2023;379:1-41. doi: 10.1016/bs.ircmb.2023.05.005. Epub 2023 Jul 1.Int Rev Cell Mol Biol. 2023.PMID:37541721
- Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation.Rincon MY, VandenDriessche T, Chuah MK.Rincon MY, et al.Cardiovasc Res. 2015 Oct 1;108(1):4-20. doi: 10.1093/cvr/cvv205. Epub 2015 Aug 3.Cardiovasc Res. 2015.PMID:26239654Free PMC article.Review.
- Viral-mediated gene transfer for cancer treatment.Wilson DR.Wilson DR.Curr Pharm Biotechnol. 2002 Jun;3(2):151-64. doi: 10.2174/1389201023378445.Curr Pharm Biotechnol. 2002.PMID:12022258Review.
- Viral and non-viral vectors in gene therapy: technology development and clinical trials.Lundstrom K, Boulikas T.Lundstrom K, et al.Technol Cancer Res Treat. 2003 Oct;2(5):471-86. doi: 10.1177/153303460300200513.Technol Cancer Res Treat. 2003.PMID:14529313Review.
- Applications of Hemagglutinating Virus of Japan in therapeutic delivery systems.Kaneda Y.Kaneda Y.Expert Opin Drug Deliv. 2008 Feb;5(2):221-33. doi: 10.1517/17425247.5.2.221.Expert Opin Drug Deliv. 2008.PMID:18248320Review.
Cited by
- Genome-based therapeutic interventions for β-type hemoglobinopathies.Karamperis K, Tsoumpeli MT, Kounelis F, Koromina M, Mitropoulou C, Moutinho C, Patrinos GP.Karamperis K, et al.Hum Genomics. 2021 Jun 5;15(1):32. doi: 10.1186/s40246-021-00329-0.Hum Genomics. 2021.PMID:34090531Free PMC article.Review.
- Gene Therapy for Neurodegenerative Diseases: Slowing Down the Ticking Clock.Martier R, Konstantinova P.Martier R, et al.Front Neurosci. 2020 Sep 18;14:580179. doi: 10.3389/fnins.2020.580179. eCollection 2020.Front Neurosci. 2020.PMID:33071748Free PMC article.Review.
- Recent Advances in Preclinical Research Using PAMAM Dendrimers for Cancer Gene Therapy.Tarach P, Janaszewska A.Tarach P, et al.Int J Mol Sci. 2021 Mar 13;22(6):2912. doi: 10.3390/ijms22062912.Int J Mol Sci. 2021.PMID:33805602Free PMC article.Review.
- Targeting DAD1 gene with CRISPR-Cas9 system transmucosally delivered by fluorinated polylysine nanoparticles for bladder cancer intravesical gene therapy.Tang D, Yan Y, Li Y, Li Y, Tian J, Yang L, Ding H, Bashir G, Zhou H, Ding Q, Tao R, Zhang S, Wang Z, Wu S.Tang D, et al.Theranostics. 2024 Jan 1;14(1):203-219. doi: 10.7150/thno.88550. eCollection 2024.Theranostics. 2024.PMID:38164146Free PMC article.
- Biopolymers augment viral vectors based gene delivery.Balakrishnan B, David E.Balakrishnan B, et al.J Biosci. 2019 Sep;44(4):84.J Biosci. 2019.PMID:31502562Review.
References
- Raper S.E., Chirmule N., Lee F.S., Wivel S.A., Bagg A., Gao G.P., Wilson J.M., Batshaw M.L. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 2003;80:148–158. doi: 10.1016/j.ymgme.2003.08.016. - DOI - PubMed
- Hacein-Bey-Abina S., Garrigue A., Wang G.P., Soulier J., Lim A., Morillon E., Clappier E., Caccavelli L., Delabesse E., Beldjord K., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Investig. 2008;118:3132–3142. doi: 10.1172/JCI35700. - DOI - PMC - PubMed
- Schiedner G., Morral N., Parks R.S., Wu Y., Koopmans S.C., Langston C., Graham F.L., Beaudet A.L., Kochanek S. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet. 1998;18:180–183. doi: 10.1038/ng0298-180. - DOI - PubMed
- Wang F., Wang Z., Tian H., Qi M., Zhai Z., Li S., Li R., Zhang H., Wang W., Fu S., et al. Biodistribution and safety assessment of bladder cancer specific oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice. Curr. Gene Ther. 2012;12:67–76. doi: 10.2174/156652312800099599. - DOI - PMC - PubMed
Publication types
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources